Last Updated: November 21, 2026

List of Excipients in Branded Drug SUDAFED SINUS CONGESTION 12 HOUR

« Back to Dashboard


SUDAFED Sinus Congestion 12 Hour Excipient Strategy, Formulation IP and Commercial Opportunities

Last updated: October 5, 2026

SUDAFED Sinus Congestion 12 Hour is an extended-release oral tablet containing pseudoephedrine hydrochloride 120 mg. Its commercial value depends on reliable 12-hour release, tablet robustness, abuse-control compliance, supply-chain security and consumer tolerability rather than new-molecule exclusivity. The active ingredient is long established, and the primary opportunity is to improve or differentiate the delivery platform.

What is the active ingredient and dosage form in SUDAFED Sinus Congestion 12 Hour?

The product contains pseudoephedrine hydrochloride 120 mg in an extended-release tablet intended for dosing every 12 hours. FDA labeling identifies pseudoephedrine hydrochloride as the nasal decongestant active ingredient and instructs adults and children 12 years and older to take one tablet every 12 hours, with a maximum of two tablets in 24 hours [1].

Attribute Product profile
Brand SUDAFED Sinus Congestion 12 Hour
Active ingredient Pseudoephedrine hydrochloride
Strength 120 mg per extended-release tablet
Route Oral
Release profile Extended release, approximately 12 hours
Therapeutic category Nasal decongestant
Primary regulatory framework FDA OTC drug requirements
Prescription status Behind-the-counter in the United States because of pseudoephedrine sales controls
Reference regulatory source FDA Drug Facts labeling and OTC nasal-decongestant requirements

The product does not depend on a biologic, injectable delivery system or complex active pharmaceutical ingredient. Formulation performance is therefore the main technical differentiator.

What excipients are used in SUDAFED Sinus Congestion 12 Hour?

Public labeling identifies a conventional solid-dose excipient system. Listed inactive ingredients include carnauba wax, colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate, stearic acid, talc and titanium dioxide [2].

Excipient Likely formulation function
Hypromellose Hydrophilic release-control matrix and film-forming polymer
Carnauba wax Hydrophobic release modulation, coating or polish
Microcrystalline cellulose Diluent and tablet-compression aid
Povidone Binder and granulation aid
Sodium starch glycolate Disintegrant
Magnesium stearate Lubricant
Stearic acid Lubricant and hydrophobicity modifier
Colloidal silicon dioxide Glidant and moisture-management aid
Talc Processing aid and anti-adherent
Titanium dioxide Opacifier and colorant

The combination indicates a matrix-based or coated-matrix extended-release design. Hypromellose and wax are the most commercially relevant release-controlling components. Microcrystalline cellulose, povidone and sodium starch glycolate support manufacturing and tablet breakup. Lubricants and glidants affect compression, ejection, dissolution and scale-up.

Exact excipient identity, grade, supplier and concentration are not generally disclosed in consumer labeling. Those parameters are often where formulation know-how resides.

How does the excipient system control 12-hour release?

Extended release requires the tablet to limit pseudoephedrine dissolution without preventing eventual drug release. Hypromellose hydrates after ingestion and forms a gel layer. Water penetration, polymer swelling, erosion and drug diffusion determine the release curve.

Carnauba wax can reduce water ingress and slow diffusion. The balance between hydrophilic polymer and hydrophobic wax affects:

  • Initial release during the first one to two hours.
  • Dose dumping risk under altered pH or mechanical stress.
  • Release consistency across tablet hardness ranges.
  • Sensitivity to food and gastrointestinal transit.
  • Stability under heat and humidity.
  • Dissolution performance after long-term storage.

Sodium starch glycolate can accelerate tablet breakup, which may conflict with prolonged release if not confined to a defined tablet region or used at a controlled concentration. Magnesium stearate and stearic acid can create hydrophobic surfaces when over-lubrication occurs, producing slower or less reproducible dissolution.

For a generic or follow-on product, matching the reference dissolution profile is a higher-value objective than simply reproducing the listed excipient names.

What formulation patents protect SUDAFED Sinus Congestion 12 Hour?

No composition-of-matter patent protects pseudoephedrine hydrochloride as a modern active ingredient. Any commercially relevant protection would more likely involve:

  1. Extended-release tablet architecture.
  2. Polymer-wax release-control systems.
  3. Coating or barrier-layer technology.
  4. Abuse-resistant or tamper-resistant delivery.
  5. Manufacturing methods that produce a defined dissolution profile.
  6. Combination products containing pseudoephedrine and another active ingredient.
  7. Packaging or dispensing systems addressing pseudoephedrine diversion.

The public product label does not establish that an active, product-specific formulation patent currently protects SUDAFED Sinus Congestion 12 Hour. Patent status should be assessed through current USPTO records, FDA Orange Book listings and relevant assignment databases before relying on a freedom-to-operate conclusion.

Because the product is an OTC extended-release tablet, patent claims directed to a particular excipient combination may face enablement, written-description and obviousness scrutiny. A formulation patent is stronger when it links defined excipient ranges to an unexpected dissolution result, improved stability, reduced dose dumping or resistance to mechanical manipulation.

What is the Orange Book status of SUDAFED Sinus Congestion 12 Hour?

The FDA Orange Book primarily covers approved prescription and certain approved nonprescription drug products. SUDAFED Sinus Congestion 12 Hour is generally regulated as an OTC product under the FDA nonprescription-drug framework rather than as a conventional prescription NDA product with a standard Orange Book patent listing.

The relevant regulatory pathway is the OTC monograph system and applicable FDA labeling requirements. FDA’s final administrative order framework for OTC drugs replaced the former monograph rulemaking process for many products, but the applicable regulatory status depends on the specific active ingredient, dosage form and product history [3].

An Orange Book absence would not mean that all intellectual-property risk is eliminated. Trade secrets, manufacturing patents, packaging patents, trademarks and private-label agreements can remain commercially relevant.

When does SUDAFED Sinus Congestion 12 Hour lose exclusivity?

Pseudoephedrine has no meaningful new-chemical-entity exclusivity remaining. The ingredient has been used in approved medicines for decades. The product’s commercial exclusivity is therefore based mainly on brand recognition, distribution, retailer placement, consumer trust and compliance with pseudoephedrine controls.

Exclusivity category Assessment
New chemical entity exclusivity Expired or inapplicable
Orphan-drug exclusivity Not applicable
Biologic exclusivity Not applicable
Pediatric exclusivity No product-specific period established from public labeling
OTC monograph exclusivity No conventional branded exclusivity comparable to prescription products
Formulation patent exclusivity Requires current patent-by-patent confirmation
Trademark protection Brand protection remains commercially relevant
Retail and distribution advantage Important but not statutory exclusivity

The absence of a current composition patent creates a relatively open technical field for generic and private-label manufacturers, subject to FDA requirements and controlled-substance sales rules.

What generic entry risks exist for SUDAFED Sinus Congestion 12 Hour?

Generic entry risk is high at the active-ingredient level and moderate at the formulation level.

A competing manufacturer can use widely available excipients, but it must demonstrate acceptable performance for an extended-release product. Key development risks include:

  • Matching the full dissolution curve rather than only the 12-hour endpoint.
  • Avoiding rapid release after tablet crushing or mechanical stress.
  • Maintaining performance across pH conditions.
  • Controlling tablet hardness and porosity.
  • Managing moisture uptake by hypromellose and starch-based excipients.
  • Preventing batch-to-batch changes caused by polymer viscosity grade.
  • Reproducing the product’s physical dimensions and swallowability.
  • Complying with pseudoephedrine transaction and sales restrictions.

A generic can compete without copying the reference product’s exact excipient list if it demonstrates equivalent performance and meets applicable FDA requirements. That creates an opportunity for lower-cost formulations based on direct compression, hydrophilic matrices, coated pellets or multilayer tablets.

What excipient strategies create commercial opportunities?

Polymer substitution and supply resilience

A manufacturer could evaluate alternative hypromellose grades, hydroxypropyl cellulose, ethylcellulose or methacrylate copolymers. The objective would be to preserve the dissolution profile while reducing dependence on a single polymer supplier.

The strongest opportunity is a platform with multiple qualified grades that tolerate normal raw-material variability. This can reduce supply disruption and simplify second-source qualification.

Abuse-resistant extended release

Pseudoephedrine is subject to diversion concerns and purchase restrictions. A formulation that resists crushing, grinding or solvent extraction could support a differentiated product, although a new formulation would need a clear regulatory and commercial rationale.

Potential approaches include:

  • High-strength polymer matrices.
  • Multiparticulate systems with functional coatings.
  • Hard-to-crush tablets.
  • Ion-exchange or complexation systems.
  • Combination barriers that limit rapid extraction.

These approaches increase manufacturing cost and may complicate regulatory comparability. They are more attractive when supported by measurable abuse-deterrence performance.

Lower-cost direct compression

Direct compression could reduce granulation steps, solvent use and equipment requirements. The main challenge is obtaining adequate content uniformity and a stable release profile with a high-dose active ingredient.

Commercially valuable excipient attributes include:

  • High flowability.
  • Low lubricant sensitivity.
  • Consistent compactibility.
  • Low moisture content.
  • Narrow particle-size distribution.
  • Compatibility with high-speed tableting.

A direct-compression formulation is most defensible when the process window is broad and the dissolution profile remains stable across production-scale changes.

Improved stability and packaging

Moisture and heat can alter polymer hydration, tablet hardness and dissolution. Opportunities include low-moisture excipient grades, protective film coatings, desiccant-integrated packaging and blister systems with improved barrier properties.

Packaging innovation may produce stronger practical protection than a narrow excipient patent if it reduces shelf-life failures and supports national retail distribution.

Patient-centered tablet design

A smaller tablet, smoother coating or reduced chalkiness can improve swallowing and consumer acceptance. Pseudoephedrine 120 mg creates a high drug-load challenge, so excipient selection must preserve tablet size while maintaining mechanical strength.

Potential commercial claims include easier swallowing, reduced tablet residue, lower friability and improved stability. Claims must remain consistent with FDA labeling rules and substantiated consumer evidence.

Which companies are challenging SUDAFED Sinus Congestion 12 Hour?

The competitive field includes private-label retailers, generic pharmaceutical manufacturers and branded OTC companies selling pseudoephedrine extended-release products. Competitive products may use the same active ingredient and similar release technologies without infringing brand trademarks.

Relevant competitor groups include:

  • Retailer-controlled store brands.
  • Generic manufacturers supplying pharmacies.
  • OTC companies selling 12-hour pseudoephedrine tablets.
  • Manufacturers of combination products containing pseudoephedrine, acetaminophen, ibuprofen or antihistamines.
  • International manufacturers using different prolonged-release technologies.

No current public record establishes a specific Paragraph IV challenger to this branded OTC product. Paragraph IV litigation is primarily associated with abbreviated new drug applications referencing listed prescription products. It is not the expected central entry mechanism for a product regulated through the OTC framework.

What patent litigation and licensing issues affect the product?

No product-specific patent litigation or settlement agreement can be established from the consumer label alone. The main legal risks are likely to involve:

  • Patent claims covering extended-release pseudoephedrine formulations.
  • Trademark infringement involving the SUDAFED name or trade dress.
  • Private-label supply and manufacturing agreements.
  • Excipient or coating technology licenses.
  • Packaging patents.
  • Confidential manufacturing know-how.

A licensing opportunity may exist for functional polymers, coated multiparticulates, abuse-deterrent technology or high-barrier packaging. No public licensing deal specific to SUDAFED Sinus Congestion 12 Hour is established in the cited FDA and labeling materials.

How strong is the patent estate for SUDAFED Sinus Congestion 12 Hour?

The apparent patent estate is weak at the molecule level and potentially meaningful only at the formulation, process or brand level.

IP category Relative strength
Pseudoephedrine molecule Very weak; longstanding active ingredient
Basic extended-release tablet Moderate technical competition; likely vulnerable to design-around
Specific polymer-wax formulation Potentially moderate if claims are narrow and supported by data
Abuse-resistant delivery Potentially stronger if performance is demonstrated
Manufacturing process Moderate if process parameters produce non-obvious results
Packaging Narrow but commercially useful
SUDAFED trademark and trade dress Stronger brand protection than ingredient exclusivity

A formulation patent should not be treated as a barrier without confirming claim scope, legal status, prosecution history, terminal disclaimers, maintenance fees and relevant family members.

What FDA regulatory issues govern new excipient strategies?

An OTC reformulation must satisfy FDA requirements for the active ingredient, dosage form, labeling, manufacturing controls and stability. Excipients should have established pharmaceutical use or require an appropriate safety justification.

Key regulatory workstreams include:

  1. Confirming that pseudoephedrine hydrochloride and the proposed dosage form remain within the applicable OTC framework.
  2. Establishing release specifications and discriminatory dissolution methods.
  3. Evaluating alcohol-induced dose dumping and altered-pH performance.
  4. Demonstrating stability under ICH conditions.
  5. Assessing excipient compatibility and extractables.
  6. Confirming tablet robustness under shipping and consumer handling.
  7. Verifying pseudoephedrine sales-control obligations.
  8. Reviewing labeling, warnings and age restrictions.

The formulation must also comply with FDA current good manufacturing practice requirements under 21 C.F.R. Parts 210 and 211 [4].

Key Takeaways

  • SUDAFED Sinus Congestion 12 Hour contains pseudoephedrine hydrochloride 120 mg in an extended-release tablet.
  • The principal excipient strategy uses hypromellose, carnauba wax, microcrystalline cellulose, povidone, sodium starch glycolate, lubricants and processing aids.
  • The active ingredient has no meaningful modern-molecule exclusivity.
  • Product differentiation depends on dissolution control, manufacturing robustness, stability, packaging and consumer usability.
  • Generic entry risk is high because competitors can design around the listed excipient system.
  • The strongest commercial opportunities are polymer substitution, direct compression, abuse-resistant delivery, moisture protection and smaller or easier-to-swallow tablets.
  • No product-specific Paragraph IV challenge, settlement agreement or licensing deal is established by the cited public materials.
  • The Orange Book is not the principal source of exclusivity analysis for this OTC product.
  • Any patent conclusion requires a current claim-level search covering formulation, manufacturing, packaging and trademark rights.

FAQs

Is pseudoephedrine hydrochloride in SUDAFED Sinus Congestion 12 Hour immediate release?

No. The product is labeled as an extended-release 120 mg tablet intended for 12-hour dosing.

Can a generic use different excipients from SUDAFED Sinus Congestion 12 Hour?

Yes. A competing product generally does not need to copy the reference product’s exact excipients, but it must satisfy applicable FDA requirements and demonstrate acceptable extended-release performance.

Does hypromellose alone create patent protection for the product?

No. Hypromellose is a widely used pharmaceutical polymer. Protection would depend on a specific formulation, concentration range, process, performance result and enforceable patent claim.

Is pseudoephedrine subject to special U.S. distribution controls?

Yes. U.S. retailers and distributors must comply with federal pseudoephedrine sales, identification, recordkeeping and purchase-limit requirements under the Combat Methamphetamine Epidemic Act and related regulations [5].

What is the best commercial white-space opportunity around this product?

The most defensible opportunity is a robust extended-release platform that combines reliable dissolution, low moisture sensitivity, broad manufacturing tolerance and improved resistance to crushing or extraction without materially increasing tablet size or cost.

References

  1. U.S. Food and Drug Administration. (n.d.). SUDAFED Sinus Congestion 12 Hour Drug Facts label. DailyMed.
  2. National Library of Medicine. (n.d.). SUDAFED 12 hour extended release tablet: Inactive ingredients and labeling information. DailyMed.
  3. U.S. Food and Drug Administration. (2024). Over-the-counter monograph drugs. https://www.fda.gov/drugs/over-counter-otc-nonprescription-medicines/over-counter-otc-drug-monograph-system
  4. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Parts 210 and 211: Current good manufacturing practice for drugs. https://www.ecfr.gov
  5. U.S. Drug Enforcement Administration. (n.d.). Pseudoephedrine and ephedrine regulated products. https://www.deadiversion.usdoj.gov/part-1314/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.